Mallinckrodt PLC (NYSE:MNK) – Analysts at Leerink Swann issued their Q2 2017 EPS estimates for Mallinckrodt PLC in a note issued to investors on Thursday. Leerink Swann analyst J. Gerberry anticipates that the firm will post earnings per share of $2.16 for the quarter. Leerink Swann currently has a “Outperform” rating and a $92.00 target price on the stock. Leerink Swann also issued estimates for Mallinckrodt PLC’s Q3 2017 earnings at $2.02 EPS, Q4 2017 earnings at $2.07 EPS, FY2019 earnings at $9.90 EPS and FY2020 earnings at $10.96 EPS.

Mallinckrodt PLC (NYSE:MNK) last released its earnings results on Tuesday, August 2nd. The company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.20. The company earned $970.60 million during the quarter, compared to analyst estimates of $920.35 million. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. Mallinckrodt PLC’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Mallinckrodt PLC from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research note on Tuesday, July 5th. TheStreet upgraded shares of Mallinckrodt PLC from a “hold” rating to a “buy” rating in a research note on Friday, June 17th. Wells Fargo & Co. restated a “buy” rating on shares of Mallinckrodt PLC in a research note on Friday, June 10th. Mizuho restated a “buy” rating on shares of Mallinckrodt PLC in a research note on Monday, June 6th. Finally, Vetr cut shares of Mallinckrodt PLC from a “strong-buy” rating to a “buy” rating and set a $72.20 target price on the stock. in a research note on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $94.66.

Mallinckrodt PLC (NYSE:MNK) opened at 76.12 on Monday. The company has a market capitalization of $8.20 billion, a price-to-earnings ratio of 14.35 and a beta of 1.52. Mallinckrodt PLC has a 12-month low of $50.90 and a 12-month high of $86.06. The stock has a 50 day moving average price of $76.09 and a 200 day moving average price of $65.27.

Several hedge funds have recently bought and sold shares of the company. Laurel Wealth Advisors Inc. increased its stake in Mallinckrodt PLC by 0.5% in the second quarter. Laurel Wealth Advisors Inc. now owns 3,427 shares of the company’s stock worth $208,000 after buying an additional 16 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Mallinckrodt PLC by 1.2% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,472 shares of the company’s stock valued at $214,000 after buying an additional 41 shares during the last quarter. Turner Investments L.P. increased its position in shares of Mallinckrodt PLC by 0.5% in the second quarter. Turner Investments L.P. now owns 19,420 shares of the company’s stock valued at $1,180,000 after buying an additional 100 shares during the last quarter. Investors Capital Advisory Services increased its position in shares of Mallinckrodt PLC by 1.2% in the second quarter. Investors Capital Advisory Services now owns 8,710 shares of the company’s stock valued at $529,000 after buying an additional 107 shares during the last quarter. Finally, LS Investment Advisors LLC increased its position in shares of Mallinckrodt PLC by 2.4% in the second quarter. LS Investment Advisors LLC now owns 5,408 shares of the company’s stock valued at $329,000 after buying an additional 126 shares during the last quarter. Hedge funds and other institutional investors own 94.76% of the company’s stock.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.